Companion Diagnostics will be presented VIRTUALLY this year due Covid-19 considerations. We have a full Virtual Environment including areas for Posters and Exhibitors for the event.

Join us at the 5th Annual COMPANION DIAGNOSTICS FORUM. During the five short years after the launch of the Precision Medicine program, the need for companion diagnostics has grown rapidly to keep pace with novel developments in pharma. Consequently, support areas have had to accelerate to catch up with technical breakthroughs, including education, regulations, and adoption in clinical applications. At this year’s forum, speakers will address how these various areas are meshing to bring better healthcare to patients.

Some of the Organizations who have Participated

CALL FOR ABSTRACTS

Each year welcomes increasing numbers of drugs and biologics supported by assays designed to indicate the safety and/or efficacy for specified populations. While this is a positive sign for precision diagnostics and therapeutics in general, several issues have arisen in the course of testing drugs and assays, e.g., finding more precise biomarkers, developing drugs for unmet needs. Solutions are being discovered, but the “elephant in the room” continues to be why only a percent of any population responds to any given therapy. And, what can be done for those patients with unmet needs? So lots left to do! Moving to the next level will take advocating for an organization-wide, systemic adoption of precision medicine to realize the full potential of this paradigm. Subsequent success requires building broad alliances in this space and making the case for market-driven uptake. For this year’s Forum, we are calling for abstracts that consider scientific, technical, and organizational solutions to issues relating to the uptake and use of precision medicine. Come join us!

Call for Abstracts

We look forward to your abstracts and participation. Event topics this year include:

Biomarkers – Discovery and Clinical Development
Technology/Frameworks
Precision Medicine
Business Models and Partnerships
Regulatory Issues
Reimbursement
Standardization
Drug and Diagnostics Pricing Transparency